NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $0.76 -0.02 (-2.58%) (As of 09/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Xilio Therapeutics alerts: Email Address About Xilio Therapeutics Stock (NASDAQ:XLO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xilio Therapeutics alerts:Sign Up Key Stats Today's Range$0.75▼$0.8250-Day Range$0.74▼$1.0152-Week Range$0.49▼$2.89Volume58,908 shsAverage Volume582,122 shsMarket Capitalization$27.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More… Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Stock News HeadlinesXilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024August 8, 2024 | investorplace.comElection Shocker: Trump Won't See This ComingIf you suspect Democrats will play dirty games in this election… You are RIGHT! Executive Order 14019 has already been called a “planned election interference program.”September 24, 2024 | Banyan Hill Publishing (Ad)Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.June 13, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14, 2024 | investorplace.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comSee More Headlines XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO shares have increased by 37.4% and is now trading at $0.7558. View the best growth stocks for 2024 here. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) posted its earnings results on Thursday, August, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The company earned $2.36 million during the quarter, compared to the consensus estimate of $30 million. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Top institutional investors of Xilio Therapeutics include Renaissance Technologies LLC (0.80%) and XTX Topco Ltd (0.08%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Bain Capital Life Sciences Inv and Rock Springs Capital Managemen. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/23/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees73Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,400,000.00 Net MarginsN/A Pretax Margin-2,780.27% Return on Equity-173.95% Return on Assets-83.00% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$2.36 million Price / Sales11.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.56Miscellaneous Outstanding Shares36,912,000Free Float34,993,000Market Cap$27.90 million OptionableNot Optionable Beta-0.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:XLO) was last updated on 9/24/2024 by MarketBeat.com Staff From Our PartnersElection Shocker: Trump Won't See This ComingIf you suspect Democrats will play dirty games in this election… You are RIGHT! Executive Order 14019 ha...Banyan Hill Publishing | SponsoredThe Fed’s New Rate Cut—The Calm Before the Storm?Former hedge fund manager: "Move your money before the Fed's next meeting on July 31" In 2022, the Federal ...Stansberry Research | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free xlo Stock Alerts